CHAMPIONS ONCOLOGY, INC. Business Acquisition, Contingent Consideration, Potential Cash Payment (Deprecated 2013-01-31)
CHAMPIONS ONCOLOGY, INC. (CSBR) had Business Acquisition, Contingent Consideration, Potential Cash Payment (Deprecated 2013-01-31) of CAD 3.00 million as of 2013-01-31, per its 10-Q filed 2013-03-13.
Discontinued › Notes
us-gaap:BusinessAcquisitionContingentConsiderationPotentialCashPayment · last filed 2013-03-13
- 2013-01-31: Business Acquisition, Contingent Consideration, Potential Cash Payment (Deprecated 2013-01-31) 3.00M CAD.
CAD
| Period end | Business Acquisition, Contingent Consideration, Potential Cash Payment (Deprecated 2013-01-31) |
|---|---|
| 2013-01-31 | 3.00M CAD 10-Q · filed 2013-03-13 |
USD
| Period end | Business Acquisition, Contingent Consideration, Potential Cash Payment (Deprecated 2013-01-31) |
|---|---|
| 2012-10-31 | $3.00M 10-Q · filed 2012-12-13 |
| 2012-07-31 | $3.00M 10-Q · filed 2012-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |